Home > Healthcare > Biotechnology > Bioservices > Upstream Bioprocessing Market

Upstream Bioprocessing Market Size

Report ID: GMI8437
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Upstream Bioprocessing Market Size

Upstream Bioprocessing Market size was valued at USD 9.5 billion in 2023 and is anticipated to grow at CAGR of 9.7% from 2024 and 2032. One of the major factors contributing to the growth is the increasing demand for biopharmaceuticals caused by high prevalence of chronic diseases.

To get key market trends

Download Free Sample

Therefore, the efficient and scalable upstream processes are essential to meet the growing demand for biopharmaceuticals & advanced therapies and address unmet medical needs. Further, the technological advancements such as single-use bioreactors, high-throughput screening, and bioreactor design, enhance productivity, efficiency, and scalability contributes to the increasing adoption of upstream bioprocessing.

Upstream bioprocessing refers to the initial stages of biotechnological production processes involved in manufacturing biological products such as pharmaceuticals, enzymes, or biofuels. It encompasses various steps from the selection and cultivation of host organisms (such as bacteria, yeast, or mammalian cells) to the preparation of the growth medium and the actual cultivation of these organisms in bioreactors or fermenters.

Upstream Bioprocessing Market Report Attributes
Report Attribute	Details
Base Year:	2023
Upstream Bioprocessing Market Size in 2023:	USD 9.5 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	9.7%
2032 Value Projection:	USD 21.6 Billion
Historical Data for:	2018 - 2023
No. of Pages:	171
Tables, Charts & Figures:	301
Segments covered:	Product, Usage Mode, Mode, Application, End-user, and Region
Growth Drivers:	Increasing adoption of single-use bioprocessing systems Rising implementation of Process Analytical Technology (PAT) Increasing demand for biopharmaceuticals High capital costs
Pitfalls & Challenges:	Technical and operational challenges related to upstream bioprocessing

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The upstream bioprocessing market was valued at USD 9.5 billion in 2023 and is anticipated to record 9.7% CAGR over 2024-2032, owing to the increasing demand for biopharmaceuticals caused by high prevalence of chronic diseases.

The bioreactors/fermenters segment accounted for a share of 48.6% in market in 2023 and will grow significantly through 2032 as these vessels provide a controlled environment for the proliferation of cells or microorganisms, essential to produce biopharmaceuticals, enzymes, vaccines, and other bioproducts.

North America upstream bioprocessing industry is estimated to reach over USD 9.5 billion by 2032 attributed to the increasing collaboration & partnerships with an aim of improving awareness and education related to bioprocessing.

Applikon Biotechnology, Boehringer Ingelheim GmbH, CellGenix GmbH, Corning, Inc., Danaher Corporation (Cytvia), Eppendorf AG, Merck KGaA, PBS Biotech, Inc., Sartorius AG, and Thermo Fisher Scientific Inc.